Steven Horwitz, MD of @sloan_kettering discusses the phase 2 PRIMO study.
_______
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key abstracts highlighting COPIKTRA®…
Guide to post-CDK4/6 inhibitor treatment for HR+/HER2- breast cancer. Learn resistance, therapies, and access with ASCO expertise.
Discover insights from the MATTERHORN trial, showcasing the impact of durvalumab combined with FLOT chemotherapy.
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.
Explore HR+/HER2- metastatic breast cancer 2L outcomes with crucial insights from ASCO 2025 on median progression-free survival.
Discover BsAb oncology & 2025 clinical trials. Explore bispecific antibodies cancer therapy on OncologyTube.com. Watch now!
Explore how China oncology trials are revolutionizing cancer research with a remarkable increase in clinical trials.
Explore HCC treatment selection with guidelines from ASCO 2025 to improve patient outcomes and management of hepatocellular carcinoma.
FDA approves taletrectinib for ROS1-positive NSCLC on June 11, 2025. Learn about trial results, dosage, and side effects in this easy guide.
Explore ASCO 2025 cancer research on treatment-induced lymphopenia and immune health. Insights for oncologists from Ohio State and Dana-Farber.
